account_id none on file
legal_name Nuvectis Pharma, Inc.
ticker NVCT
cik 1875558
domain nuvectis.com
linkedin_company_url none on file
entry_point_account_id none on file
name Nuvectis Pharma Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 6 executives 0 family 0
why_nownone on file
callsnone on file
filings
These expenses also cover insurance costs, investor relations activities, travel expenses, and facility costs not otherwise included in research and development expenses.
filing / Aug 4, 2026 / receipt
We rent our office space in Fort Lee, New Jersey, based on a one-year agreement signed on May 1, 2026. Off-Balance Sheet Arrangements We did not have any off-balance sheet arrangements during the periods presented, and we do not currently have any, as defined in the rules and regulations of the SEC.
filing / Aug 4, 2026 / receipt
We intend to use the net proceeds of these offerings to fund the development of NXP100, NXP200 and NXP900, to continue development and sponsored research related to our current product candidates or any future product candidate, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes.
filing / Aug 4, 2026 / receipt
General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees paid for accounting, auditing, consulting, and tax services; insurance costs; investor relations activities; travel expenses; and facility costs not otherwise included in research and development expenses.
filing / May 5, 2026 / receipt
We rent our office space in Fort Lee, New Jersey, based on a one-year agreement renewed on May 1, 2026. Off-Balance Sheet Arrangements We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.
filing / May 5, 2026 / receipt
We intend to use the net proceeds of the offering to fund the Phase 1 development of NXP900, to continue development and sponsored research related to our current product candidates or any future product candidate, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes.
filing / May 5, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-03 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug nuvectis-pharma-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$